Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 34 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Ranolazine 500 MG Clear all

Conditions: Sudden Cardiac Death, Ventricular Arrythmias
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Aspirus Heart and Vascular Institute-Research and Education; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Wausau, Wisconsin

Conditions: Heart; Dysfunction Postoperative, Cardiac Surgery
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Corewell Health East; Other
Eligibility: 22 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Royal Oak, Michigan • Troy, Michigan

Conditions: Stable Angina, Metabolic Syndrome
Interventions: Ranolazine, Placebo; Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 30 Years to 75 Years · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Microvascular Angina
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 30 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Drug-induced QT Prolongation, Pharmacokinetics, Pharmacodynamics
Interventions: Ranolazine, Verapamil, Lopinavir / Ritonavir, Chloroquine, Placebo, Dofetilide and Diltiazem; Drug
Lead sponsor: Food and Drug Administration (FDA); Federal
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Premature Ventricular Beats
Interventions: Ranolazine; Drug
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Coronary Artery Disease, Pain, Peripheral Nervous System Diseases, Polyneuropathy
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Houma, Louisiana

Conditions: Pulmonary Hypertension, Diastolic Left Ventricular Dysfunction
Interventions: Ranolazine; Drug
Lead sponsor: Boston University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: ALS
Interventions: Ranolazine 500 MG, Ranolazine 1000 MG; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Coronary Artery Disease, Angina Pectoris
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 2,651 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 86
States / cities: Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 74 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 9
States / cities: Escondido, California • Los Angeles, California • Miami, Florida + 6 more

Conditions: Myocardial Ischemia, Coronary Artery Disease, Arteriosclerosis, Chronic Stable Angina
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: East Carolina University; Other
Eligibility: 21 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Greenville, North Carolina

Conditions: Ranolazine, Diastolic Heart Failure, Tissue Doppler Ultrasound, Echocardiography
Interventions: ranolazine; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: San Diego, California

Conditions: Myocardial Perfusion Imaging, Myocardial Ischemia
Interventions: Ranolazine, Placebo to match ranolazine, SPECT MPI, Exercise; Drug · Procedure · Behavioral
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 26
States / cities: Birmingham, Alabama • Imperial, California • Lincoln, California + 23 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Metformin, Ranolazine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Diabetes, Type I, Diabetes, Type II, Angina, Coronary Artery Disease
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 90 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Heart Failure With Preserved Ejection Fraction
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: San Diego, California

Conditions: Microvascular Coronary Dysfunction (MCD)
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 2
States / cities: Los Angeles, California • Gainesville, Florida

Conditions: Angina
Interventions: Ranolazine, Sugar pill; Drug
Lead sponsor: North Florida Foundation for Research and Education; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Coronary Artery Disease, Angina, Metabolic Syndrome
Interventions: Ranolazine; Drug
Lead sponsor: Atlanta Heart Specialists, LLC; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Cumming, Georgia • Tucker, Georgia

Conditions: Type 2 Diabetes Mellitus
Interventions: Ranolazine, Placebo, Diet, Exercise; Drug · Behavioral
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 57
States / cities: Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 49 more

Conditions: Chronic Stable Angina, Coronary Artery Disease, Atrial Fibrillation, Ventricular Tachycardia
Interventions: ranolazine, placebo; Drug
Lead sponsor: Cardiovascular Consultants of Nevada; Other
Eligibility: 35 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Henderson, Nevada • Las Vegas, Nevada

Conditions: Type 2 Diabetes Mellitus
Interventions: Ranolazine, Placebo to match ranolazine, Metformin, Placebo to match metformin, Diet, Exercise; Drug · Behavioral
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 442 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 60
States / cities: Gulf Shores, Alabama • Little Rock, Alaska • Chandler, Arizona + 53 more

Conditions: Angina Pectoris, Coronary Artery Disease, Type 2 Diabetes Mellitus
Interventions: Ranolazine, Ranolazine placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 949 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 20
States / cities: Little Rock, Arkansas • Merced, California • Moreno Valley, California + 17 more

Search by objective public record fields.

Effect of Ranolazine on Arrhythmias and Microvolt T- Wave Alternans (MVTWA) Patients With LV Dysfunction

Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery

Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome

Ranolazine and Microvascular Angina by PET in the Emergency Department

CiPA Phase 1 ECG Biomarker Validation Study

Study to Reduce Symptoms of Premature Beats With Ranolazine

Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy

Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction

Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis

Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)

Exploratory Study to Access the Metabolic Effects of Ranolazine in Subjects With Type 2 Diabetes Mellitus When Added to Ongoing Non-insulin Antidiabetic Therapy

Efficacy of Ranolazine in Patients With Chronic Total Occlusions of Coronary Arteries

Effect of Ranolazine on Echocardiographic Indices of Diastolic Dysfunction

Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging

Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg

Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD

The Effects of Ranolazine on Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction

Treatment With Ranolazine in Microvascular Coronary Dysfunction (MCD): Impact on Angina Myocardial Ischemia

Ranolazine Among Unrevascularized Chronic Stable Angina Patients

Ranolazine, Ethnicity and the Metabolic Syndrome

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

Safety of Amiodarone and Ranolazine Together in Patients With Angina

A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone

Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina